Should FDA Grant Accelerated Approval to Duchenne Muscular Dystrophy Gene Therapy?

(MedPage Today) -- On May 12, independent experts narrowly recommended that the FDA grant accelerated approval to Sarepta's new gene therapy, SRP-9001 (delandistrogene moxeparvovec), for the treatment of Duchenne muscular dystrophy (DMD). These...
Source: MedPage Today Neurology - Category: Neurology Source Type: news